>
Switch to:

Altamira Therapeutics PS Ratio

: 52.42 (As of Today)
View and export this data going back to 2014. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Altamira Therapeutics's share price is $1.73. Altamira Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 was $0.03. Hence, Altamira Therapeutics's PS Ratio for today is 52.42.

Good Sign:

Altamira Therapeutics Ltd stock PS Ratio (=51.82) is close to 1-year low of 51.82

The historical rank and industry rank for Altamira Therapeutics's PS Ratio or its related term are showing as below:

NAS:CYTO' s PS Ratio Range Over the Past 10 Years
Min: 51.82   Med: 94.24   Max: 133.33
Current: 66.54

51.82
133.33

During the past 10 years, Altamira Therapeutics's highest PS Ratio was 133.33. The lowest was 51.82. And the median was 94.24.

NAS:CYTO's PS Ratio is ranked lower than
99.99% of the 251 Companies
in the Biotechnology industry.

( Industry Median: 14.74 vs. NAS:CYTO: 66.54 )

Altamira Therapeutics's Revenue per Sharefor the six months ended in Jun. 2021 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 was $0.03.

Back to Basics: PS Ratio


Altamira Therapeutics PS Ratio Historical Data

The historical data trend for Altamira Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PS Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 79.39

Altamira Therapeutics Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 79.39 -

Competitive Comparison

For the Biotechnology subindustry, Altamira Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Altamira Therapeutics PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's PS Ratio falls into.



Altamira Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Altamira Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.73/0.033
=52.42

Altamira Therapeutics's Share Price of today is $1.73.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Altamira Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 was $0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Altamira Therapeutics  (NAS:CYTO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Altamira Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics Business Description

Altamira Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
8 The Green, Suite 12455, Dover, DE, USA, 19901
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)